1 황성주, "펠로디핀 방출연장형 펠렛의 용출 특성 평가" 한국약제학회 37 (37): 193-196, 2007
2 R. Kamineni, "ketorolac tromethamine: oral vs transdermal iontophoresis, plasma concentration-time profiles" 32 : 50-52, 1995
3 H. Zia, "ketorolac tromethamine and ketoprofen suppositories: release profiles and bioavailability of a cocoa butter base formula in rabbits" 2 : 390-393, 1998
4 D.K. Fuller, "ketorolac and gastrointestinal ulceration" 27 : 978-979, 1993
5 J.E. Wiedrick, "Upper gastrointestinal bleeding associated with oral ketorolac therapy" 28 : 1109-, 1994
6 S.D. Roy, "Transdermal delivery of ketorolac tromethamine: permeation enhancement device design, and pharmacokinetics in healthy humans" 84 : 1190-1196, 1995
7 M. Vakily, "The problem of racemization in the stereospecific assay and pharmacokinetic evaluation in ketorolac in human and rats" 12 : 1652-1657, 1995
8 P. Maden, "Sustained release drug delivery system; Part I-an overview" 2 (2): 23-, 1985
9 M. Brandl, "Racemization of ketrotolac in aqueous solution" 84 : 1045-1048, 1995
10 U.K Jee, "Preparation and evaluation of hydrogel of ketorolac for transdermal formulation" 33 (33): 21-28, 1999
1 황성주, "펠로디핀 방출연장형 펠렛의 용출 특성 평가" 한국약제학회 37 (37): 193-196, 2007
2 R. Kamineni, "ketorolac tromethamine: oral vs transdermal iontophoresis, plasma concentration-time profiles" 32 : 50-52, 1995
3 H. Zia, "ketorolac tromethamine and ketoprofen suppositories: release profiles and bioavailability of a cocoa butter base formula in rabbits" 2 : 390-393, 1998
4 D.K. Fuller, "ketorolac and gastrointestinal ulceration" 27 : 978-979, 1993
5 J.E. Wiedrick, "Upper gastrointestinal bleeding associated with oral ketorolac therapy" 28 : 1109-, 1994
6 S.D. Roy, "Transdermal delivery of ketorolac tromethamine: permeation enhancement device design, and pharmacokinetics in healthy humans" 84 : 1190-1196, 1995
7 M. Vakily, "The problem of racemization in the stereospecific assay and pharmacokinetic evaluation in ketorolac in human and rats" 12 : 1652-1657, 1995
8 P. Maden, "Sustained release drug delivery system; Part I-an overview" 2 (2): 23-, 1985
9 M. Brandl, "Racemization of ketrotolac in aqueous solution" 84 : 1045-1048, 1995
10 U.K Jee, "Preparation and evaluation of hydrogel of ketorolac for transdermal formulation" 33 (33): 21-28, 1999
11 D. Jung, "Pharmacokinetics of ketorolac and p-hydroxyketorolac following oral and intramuscular administration of ketorolac tremethanmine" 6 : 62-65, 1989
12 S.H Kwak, "Pharmacokinetic Evaluation of ketorolac Tromethamine Sustained-Release Pellets after Oral Administration in Rabbits" 30 (30): 241-246, 2000
13 S.D. Roy, "Permeability of pure enantiomers of ketorolac through human cadaver skin" 84 : 987-990, 1995
14 S.D. Roy, "Permeability of ketorolac acid and its ester analogs (prodrug) through human cadaver skin" 83 : 1548-1553, 1994
15 K. Park, "Passive versus electrotransport-facilitated transdermal absorption of ketorolac" 63 : 303-315, 1998
16 S.T. Borodkin, "Linear drug release from laminated hydroxypropylcellulose-polyvinyl acetate films" 64 : 1289-1293, 1975
17 L. Gu, "Kinetics and mechanisms of the autoxidation of ketorolac tromethamine in aqueous solution" 41 : 95-104, 1988
18 L. Gu, "Kinetics and mechanisms of the autoxidation of ketorolac tromethamine in aqueous solution" 41 : 95-104, 1988
19 M.S Gordon, "Ketorolac tromethamine bioavailability via tablet, capsule, and oral solution dosage forms" 21 : 1143-1115, 1995
20 R.C.C. Fu, "In vitro rabbit corneal permeability study of ketorolac tromethamine, a nonsteroidal anti-inflammatory agent" 12 : 2403-2430, 1986
21 A. Rubinstein, "Gastrointestinal-physiological variables affecting the performance of oral sustained release dosage forms. Oral sustained release formulation ; design and formulation"
22 B.A. Sathyamurthy, "Formulation and evaluation of ketorolac tromethamine gels" 41 : 135-136, 1998
23 L. Genc, "Film coated enteric tablet formulation of ketorolac tromethamine" 23 : 1007-1011, 1997
24 C. Madhu, "Effect of benzalkonium chloride/EDTA on the ocular bioavailability of ketorolac tromethamine following ocular instillation to normal and de-epithelialized corneas of rabbits" 85 : 415-418, 1996
25 K. Devi, "Development and evaluation of free films and transdermal patches of ketorolac tromethamine using polymers and pressure sensitive adhesives" 41 : 97-100, 1998
26 M.A. Campanero, "Determination of ketorolac enantiomers in plasma using enantioselective liquid chromatogtaphy: application to pharmacokinetic studies" 48 : 203-208, 1998
27 D.M. Lidgate, "Corneal permeability of ketorolac tromethamine when formulated with tobramycin" 15 : 1779-1795, 1989
28 J.P. Yee, "Comparison of intramuscular ketorolac tromethamine and morphine sulfate for analgesia of pain after major surgery" 6 : 253-261, 1986
29 D.M. Brahmankar, "Cellulose matrices for controlled release of ketorolac tromethamine" 33 : 120-123, 1996
30 M. Brandl, "Approaches for improving the stability of ketorolac in power blends" 84 : 1151-1153, 1995
31 G.. Ballard, "An overview of prolonged action drug dosage forms, in sustained and controlled release drug delivery system" Marcel Dekker, Inc. 1-69, 1978
32 S.D. Roy, "Absorption of transdermally delivered ketorolac acid in humans" 84 : 49-52, 1995
33 J.A. Cordero, "A comparative study of the transdermal penetration of a series of nonsteroidal anti-inflammatory drugs" 86 : 503-508, 1997
국립중앙도서관 "우편 복사 서비스"로 연결 됩니다.
ScienceON
KISS
